Objectives
The Proteomics Unit specializes in conducting proteomic tests and analyses for R&D in cancer and infectious disease research. Emphasizing large-scale studies, the unit explores the structures and functions of proteins in depth.
Areas of impact and applications in the field
The discovery of biomarkers using proteomics aids early tumor diagnosis, prognosis, and treatment. Proteins found in the blood produced from cells and surrounding tissues contain critical biological information that has the potential to revolutionize early diagnostic, prognostic, therapeutic, and even preventative decisions in medicine.
The Proteomics Unit of AnkaTheraHub will play a a crucial role in infectious diseases, particularly emerging and re-emerging RNA viral infections. The relapse threatens the pre-antibiotic era with the increasing prevalence of microorganisms with multiple resistance to antibiotics or other agents. Thus, the search for new options for effective control of infectious diseases is becoming increasingly important. With the aid of proteomics, the function of pathogens and hosts can now be considered globally, with the genome sequences as the basis for the monitoring of proteins, their modifications, and interactions. With bioinformatics and the new technical applications, it is now increasingly possible to characterize complex samples and this opens new avenues for therapeutic possibilities.
Services
- High-Performance Liquid Chromatography HPLC
- Protein Sequencing
- LC-MS-MS protein identification
- Intact protein analysis MW Determination MS
- Proteomics Accredited Services (Process is ongoing)
- Purity Analysis of Synthetic Oligonucleotides in HPLC
- Detection and Quantification of Short-Chain Peptides by Ultra Performance Liquid Chromatography–High-Resolution Accurate Mass Spectrometry (UPLC-HRAM)
